{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:39Z","timestamp":1792788279744,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The 2025 Medical Science and Technology Projects of Sichuan Provincial Health Commission","award":["25QNMP080"],"award-info":[{"award-number":["25QNMP080"]}]},{"name":"The 2025 research project from the Sichuan Provincial Administration of Traditional Chinese Medicine","award":["25MSZX347"],"award-info":[{"award-number":["25MSZX347"]}],"id":[{"id":"https:\/\/ror.org\/03x55t826","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sichuan Province Centralised Guidance for Local Science and Technology Development Project","award":["2024ZYD0334"],"award-info":[{"award-number":["2024ZYD0334"]}]},{"name":"Sichuan Medical Association 2024 Special Research Project","award":["SC202401"],"award-info":[{"award-number":["SC202401"]}],"id":[{"id":"https:\/\/ror.org\/00ft2kj97","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Wu Jieping Medical Foundation 2024 Special Research Project on Tumour Immunity","award":["320.6750.2024-6-129"],"award-info":[{"award-number":["320.6750.2024-6-129"]}],"id":[{"id":"https:\/\/ror.org\/05dgwj702","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conversion hepatectomy has become feasible for selected patients with initially unresectable hepatocellular carcinoma (HCC), with comparative studies reporting longer survival after surgery. We performed a systematic review, meta-analysis, and quantitative bias analysis (QBA) to assess whether residual selection and time-dependent treatment bias could account for the reported benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed comparative studies of conversion or salvage hepatectomy versus non-surgical management in initially unresectable HCC and pooled endpoint-specific HRs for OS and PFS\/EFS using random-effects models. For each estimate, we extracted the time origin, exposure definition, and adjustment model. Risk of bias and certainty of evidence were assessed using ROBINS-I and GRADE. Robustness to unmeasured confounding, immortal time bias, and small-study effects was evaluated using E-values, tipping-point analysis, probabilistic QBA, timing-bias scenario analyses, and funnel-plot diagnostics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen studies contributed 24\u00a0h: 14 for OS and 10 for PFS\/EFS. Hepatectomy was associated with lower hazards of death (HR 0.33, 95% CI 0.22\u20130.48) and progression or event (HR 0.41, 95% CI 0.28\u20130.59), although heterogeneity was substantial and both prediction intervals crossed 1.0. E-values suggested robustness to moderate unmeasured confounding, whereas extreme surgical-candidacy confounding attenuated the median bias-adjusted HR to 0.82 for OS and 1.02 for PFS\/EFS. Immortal-time bias scenarios did not fully account for the observed associations. OS small-study-effect diagnostics suggested funnel-plot asymmetry, although sample-size-based Peters-type regression was not significant. Certainty of evidence was very low for both endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Conversion hepatectomy was associated with better observed survival outcomes in selected patients with initially unresectable HCC after conversion-intent therapy. The association was robust to moderate, but not extreme, assumptions about unmeasured surgical-candidacy confounding. These findings should be interpreted as a composite post-conversion association reflecting surgical clearance, treatment response, favorable tumor biology, and patient selection rather than as the isolated causal effect of hepatectomy. Future studies should report surgical eligibility landmarks, time zero, time to hepatectomy, and reasons for non-resection to clarify the independent contribution of surgery within conversion pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      PROSPERO CRD420261382843 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=1382843\" ext-link-type=\"uri\">https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=1382843<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-026-04498-x","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:15:39Z","timestamp":1784189739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Conversion hepatectomy and survival in initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis with quantitative bias analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Wenguang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xialin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8133-4082","authenticated-orcid":false,"given":"Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"6","key":"4498_CR1","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365.","journal-title":"Hepatology"},{"issue":"4","key":"4498_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"5","key":"4498_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35(5):448\u201357.","journal-title":"Ann Oncol"},{"issue":"1","key":"4498_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-025-02498-z","volume":"11","author":"X Zhang","year":"2026","unstructured":"Zhang X, Cai H, Peng W, Wang H, Wu J, Zhu X, et al. Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study. Signal Transduct Target Ther. 2026;11(1):37.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4498_CR5","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-024-12772-y","volume":"24","author":"H Xu","year":"2024","unstructured":"Xu H, Zhang H, Li B, Chen K, Wei Y. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer. 2024;24(1):1008.","journal-title":"BMC Cancer"},{"issue":"1","key":"4498_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12885-025-15449-2","volume":"26","author":"L Hu","year":"2026","unstructured":"Hu L, Xu Y, Qiao Y, Wang A, He C, Wang R. The effectiveness and safety of immune checkpoint inhibitors in conversion or neoadjuvant therapy for hepatocellular carcinoma: a meta-analysis and systematic review. BMC Cancer. 2026;26(1):163.","journal-title":"BMC Cancer"},{"issue":"1","key":"4498_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12957-024-03645-6","volume":"22","author":"J Wang","year":"2024","unstructured":"Wang J, Hu Y, Zhou L, Yang Y, Chen J, Chen H, et al. Non-surgery strategy versus hepatectomy in hepatocellular carcinoma patients with complete response after conversion therapy: a meta-analysis. World J Surg Oncol. 2024;22(1):349.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"4498_CR8","doi-asserted-by":"publisher","first-page":"107327481878935","DOI":"10.1177\/1073274818789355","volume":"25","author":"P Agarwal","year":"2018","unstructured":"Agarwal P, Moshier E, Ru M, Ohri N, Ennis R, Rosenzweig K, et al. Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the national cancer database. Cancer Control. 2018;25(1):1073274818789355.","journal-title":"Cancer Control"},{"key":"4498_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hernan","year":"2016","unstructured":"Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70\u20135.","journal-title":"J Clin Epidemiol"},{"key":"4498_CR10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4498_CR11","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester: Wiley; 2019.","edition":"2"},{"issue":"3","key":"4498_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s00268-022-06803-7","volume":"47","author":"T Yoh","year":"2023","unstructured":"Yoh T, Ishii T, Nishio T, Koyama Y, Ogiso S, Fukumitsu K, et al. A conceptual classification of resectability for hepatocellular carcinoma. World J Surg. 2023;47(3):740\u20138.","journal-title":"World J Surg"},{"issue":"8","key":"4498_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hernan","year":"2016","unstructured":"Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"4498_CR14","doi-asserted-by":"publisher","first-page":"e2558192","DOI":"10.1001\/jamanetworkopen.2025.58192","volume":"9","author":"N Simon-Tillaux","year":"2026","unstructured":"Simon-Tillaux N, Manzanilla A, Filleron T. Target Trial Emulation-A Unifying Approach for Causal Inference From Observational Data. JAMA Netw Open. 2026;9(2):e2558192.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"4498_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4498_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1536867X20909696","volume":"20","author":"A Linden","year":"2020","unstructured":"Linden A, Mathur MB, VanderWeele TJ. Conducting sensitivity analysis for unmeasured confounding in observational studies using E-values: the evalue package. Stata J. 2020;20(1):162\u201375.","journal-title":"Stata J"},{"issue":"1","key":"4498_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-023-01906-8","volume":"23","author":"E Kawabata","year":"2023","unstructured":"Kawabata E, Tilling K, Groenwold RHH, Hughes RA. Quantitative bias analysis in practice: review of software for regression with unmeasured confounding. BMC Med Res Methodol. 2023;23(1):111.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"4498_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492\u20139.","journal-title":"Am J Epidemiol"},{"key":"4498_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jcrc.2016.07.017","volume":"36","author":"M Jones","year":"2016","unstructured":"Jones M, Fowler RJ. Immortal time bias in observational studies of time-to-event outcomes. J Crit Care. 2016;36:195\u20139.","journal-title":"J Crit Care"},{"issue":"3","key":"4498_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1\u201348.","journal-title":"J Stat Softw"},{"key":"4498_CR21","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2026","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2026."},{"issue":"1","key":"4498_CR22","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1186\/s12885-025-14543-9","volume":"25","author":"QY Chi","year":"2025","unstructured":"Chi QY, Liu QY, Wang SJ, Liu YD, Gao XD, Lin KY, et al. Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study. BMC Cancer. 2025;25(1):1162.","journal-title":"BMC Cancer"},{"key":"4498_CR23","doi-asserted-by":"publisher","first-page":"103217","DOI":"10.1016\/j.eclinm.2025.103217","volume":"83","author":"W Gao","year":"2025","unstructured":"Gao W, Pan ZL, Zhao XH, Yang L, Cao JB, Li DY, et al. Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study). EClinicalMedicine. 2025;83:103217.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"4498_CR24","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/ags3.70034","volume":"9","author":"Y Goto","year":"2025","unstructured":"Goto Y, Mihara Y, Niizeki T, Sakai H, Ogasawara S, Akiba J, et al. Surgical and oncological outcomes of conversion surgery after hepatic arterial infusion chemotherapy for initially unresectable locally advanced hepatocellular carcinoma. Ann Gastroenterol Surg. 2025;9(5):1075\u201385.","journal-title":"Ann Gastroenterol Surg"},{"key":"4498_CR25","doi-asserted-by":"publisher","first-page":"1110689","DOI":"10.3389\/fonc.2023.1110689","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Chen J, Wang X, Bai T, Lu S, Wei T, et al. Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors. Front Oncol. 2023;13:1110689.","journal-title":"Front Oncol"},{"issue":"2","key":"4498_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000547725","volume":"15","author":"S Lin","year":"2025","unstructured":"Lin S, Song Z, Chen P, Yu X, Xie W, Hua Y, et al. Conversion therapy based on TACE\/HAIC-based treatment to improve the therapeutic effect of initially unresectable hepatocellular carcinoma. Liver Cancer. 2025;15(2):254\u201384.","journal-title":"Liver Cancer"},{"key":"4498_CR27","doi-asserted-by":"publisher","first-page":"1471017","DOI":"10.3389\/fimmu.2024.1471017","volume":"15","author":"YC Lu","year":"2024","unstructured":"Lu YC, Yang YC, Ma D, Wang JQ, Hao FJ, Chen XX, et al. FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study. Front Immunol. 2024;15:1471017.","journal-title":"Front Immunol"},{"key":"4498_CR28","doi-asserted-by":"publisher","first-page":"112492","DOI":"10.1016\/j.intimp.2024.112492","volume":"137","author":"B Pang","year":"2024","unstructured":"Pang B, Zuo B, Huang L, You X, Liu T, Hao J, et al. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma. Int Immunopharmacol. 2024;137:112492.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"4498_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000543994","volume":"14","author":"M Piao","year":"2025","unstructured":"Piao M, Li C, Huang Z, Zhang N, Li J, Yang X, et al. Conversion surgery after immune checkpoint inhibitor-based combination therapy for initially unresectable hepatocellular carcinoma: a retrospective cohort study. Liver Cancer. 2025;14(4):456\u201373.","journal-title":"Liver Cancer"},{"issue":"8","key":"4498_CR30","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1093\/oncolo\/oyae032","volume":"29","author":"L Wang","year":"2024","unstructured":"Wang L, Feng JK, Lu CD, Wu JY, Zhou B, Wang K, et al. Salvage surgery for initially unresectable HCC with PVTT converted by locoregional treatment plus tyrosine kinase inhibitor and anti-PD-1 antibody. Oncologist. 2024;29(8):e1041\u201350.","journal-title":"Oncologist"},{"issue":"1","key":"4498_CR31","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1038\/s41598-025-88813-8","volume":"15","author":"Z Xue","year":"2025","unstructured":"Xue Z, Yao M, Chen K, Huang T, Li J, Chen J, et al. Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma. Sci Rep. 2025;15(1):4188.","journal-title":"Sci Rep"},{"issue":"11","key":"4498_CR32","doi-asserted-by":"publisher","first-page":"101587","DOI":"10.1016\/j.jhepr.2025.101587","volume":"7","author":"DL Yang","year":"2025","unstructured":"Yang DL, Yan YH, Lai YC, Wu MS, Dong XF, Chen YZ, et al. Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004). JHEP Rep. 2025;7(11):101587.","journal-title":"JHEP Rep"},{"issue":"5","key":"4498_CR33","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1245\/s10434-022-12530-z","volume":"30","author":"XD Zhu","year":"2023","unstructured":"Zhu XD, Huang C, Shen YH, Xu B, Ge NL, Ji Y, et al. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma. Ann Surg Oncol. 2023;30(5):2782\u201390.","journal-title":"Ann Surg Oncol"},{"key":"4498_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12876-026-04677-w","volume":"26","author":"Z Sun","year":"2026","unstructured":"Sun Z, Wang Y, Tan Z, Zhou J, Chen X, Li O, et al. Prognostic outcomes of surgery vs. non-surgery in initially unresectable HCC with successful conversion via ICI\u2009+\u2009TKI therapy. BMC Gastroenterol. 2026;26:182.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"4498_CR35","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1245\/s10434-024-14944-3","volume":"31","author":"JY Wu","year":"2024","unstructured":"Wu JY, Wu JY, Fu YK, Ou XY, Li SQ, Zhang ZB, et al. Outcomes of salvage surgery versus non-salvage surgery for initially unresectable hepatocellular carcinoma after conversion therapy with transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibody: a multicenter retrospective study. Ann Surg Oncol. 2024;31(5):3073\u201383.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"4498_CR36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000536376","volume":"13","author":"ZX Zeng","year":"2024","unstructured":"Zeng ZX, Wu JY, Wu JY, Zhang ZB, Wang K, Zhuang SW, et al. Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery. Liver Cancer. 2024;13(5):498\u2013508.","journal-title":"Liver Cancer"},{"issue":"1","key":"4498_CR37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12885-023-10898-z","volume":"23","author":"C Huang","year":"2023","unstructured":"Huang C, Zhu XD, Shen YH, Xu B, Wu D, Ji Y, et al. Radiographic and alpha-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study. BMC Cancer. 2023;23(1):416.","journal-title":"BMC Cancer"},{"issue":"5","key":"4498_CR38","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1097\/JS9.0000000000001155","volume":"110","author":"B Li","year":"2024","unstructured":"Li B, Wang C, He W, Qiu J, Zheng Y, Zou R, et al. Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study. Int J Surg. 2024;110(5):2545\u201355.","journal-title":"Int J Surg"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04498-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04498-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04498-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:04:02Z","timestamp":1791806642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04498-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4498"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04498-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This systematic review used data from published studies and did not involve new recruitment of human participants, human tissue, or individual patient-level data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"391"}}